Apellis Pharmaceuticals (STU:1JK) Beginning Cash Position : €381.7 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Apellis Pharmaceuticals Beginning Cash Position?

Apellis Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2025 was €381.7 Mil.

Apellis Pharmaceuticals's quarterly Beginning Cash Position increased from Sep. 2024 (€325.6 Mil) to Dec. 2024 (€380.3 Mil) and increased from Dec. 2024 (€380.3 Mil) to Mar. 2025 (€381.7 Mil).

Apellis Pharmaceuticals's annual Beginning Cash Position declined from Dec. 2022 (€605.8 Mil) to Dec. 2023 (€507.2 Mil) and declined from Dec. 2023 (€507.2 Mil) to Dec. 2024 (€336.4 Mil).

Apellis Pharmaceuticals Beginning Cash Position Historical Data

The historical data trend for Apellis Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Beginning Cash Position Chart

Apellis Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

289.33

501.84

605.82

507.17

336.45

Apellis Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Beginning Cash Position	Get a 7-Day Free Trial															324.12	303.81	325.65	380.32	381.67

Apellis Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Apellis Pharmaceuticals Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Apellis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (STU:1JK) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

APLS:USA 1JK:Germany

Address

100 Fifth Avenue, Waltham, MA, USA, 02451

Website

https://www.apellis.com

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Apellis Pharmaceuticals Headlines

No Headlines